Binnopharm Group and NIIKEL – Branch of ICG SB RAS Join Forces to Develop Cutting-Edge Drug Products

Binnopharm Group and Research Institute of Clinical and Experimental Lymphology (NIIKEL), a branch of the Federal State Budgetary Scientific Institution Federal Research Centre Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences (NIIKEL, a branch of ICG SB RAS), signed a strategic cooperation agreement.

The main goal of the partnership is to develop an original innovative drug in the field of gastroenterology with a fundamentally new mode of action for treatment of gastrointestinal diseases. The development is expected to be completed by the end of 2027. The market potential of the new drug is estimated at 10 billion roubles in the Russian Federation.

Gastroenterology is one of the key areas in the Binnopharm Group portfolio, including more than 20 prescription and over-the-counter drugs that hold leading positions on their target markets. The company plans to expand its presence on this market both in Russia and abroad.

The task of the NIIKEL scientists includes developing the technology for synthesis of the drug, studying its properties and subsequent transfer of developed technologies to the production site of Binnopharm Group.

«We are pleased to announce the start of strategic cooperation with the Institute of Cytology and Genetics of the RAS Siberian Branch. It is an important step in the development of innovative solutions in the field of gastroenterology. The goal of the first project is to create a drug with a fundamentally new mode of action that can significantly improve the quality of life in patients with gastrointestinal disorders. We are confident that this project is by far not the last one, and our partnership will become an example of successful interaction between science and business in Russia» emphasised Rustem Muratov, CEO of Binnopharm Group.

«Our institute has accumulated vast experience in the field of pharmacological technologies. Suffice to say that we have been conducting research in this area for more than 30 years. Today the importance of developing original domestically produced drugs is beyond doubt. We are confident that the experience and knowledge accumulated by staff scientists of Research Institute of Clinical and Experimental Lymphology will allow us, together with Binnopharm Group, to create new and effective drug products» commented Maxim Korolev, Doctor of Medical Sciences, Head of Research Institute of Clinical and Experimental Lymphology, a branch of ICG SB RAS.

«Cooperation with Binnopharm Group opens up new opportunities for implementation of our scientific developments in practical medicine. We are proud that our research will become the basis for creation of an innovative drug that will help millions of patients combat gastrointestinal diseases in the Russian Federation and abroad. By combining scientific potential and production power, we create a platform for real discoveries. This collaboration not only strengthens domestic healthcare, but also creates the basis for our innovative developments to go global» pointed out Alexey Kochetov, Academician of the Russian Academy of Sciences and Director of Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences.

Besides gastroenterology, Binnopharm Group is considering the possibility of cooperation with research centres in such areas as gynaecology, surgery and neurology.